SURVEY ON THE IMPACT OF ANTICANCER DRUG SHORTAGES ON THE MANAGEMENT OF PATIENTS

Yassine Atbib*, Hajar ZHAR2, Safaa El Marnissi, Yassir Bousliman

ABSTRACT

Introduction: Shortages of anticancer drugs are a growing problem affecting the continuity of treatments and the quality of care for cancer patients. They are mainly the result of production difficulties, economic constraints, logistical weaknesses, and a strong dependence on a limited number of manufacturers. Methods: A descriptive survey was conducted with 25 healthcare professionals using a structured questionnaire, highlighting data on the frequency of shortages, the drugs involved, perceived causes, clinical and psychological impacts, as well as management strategies implemented. Results: The majority of participants report having encountered several anticancer drug shortages over the past 12 months. The affected molecules are mostly standard chemotherapies. The most frequently cited causes include production problems, supply difficulties, and increased demand. The most notable impacts are: treatment delays, therapeutic adjustments, and resorting to less effective alternatives. Discussion: The results confirm the findings of the international literature, showing that anticancer drug shortages are frequent, multifactorial, and have significant consequences. The professionals interviewed highlight the need to improve alert systems, coordination among stakeholders, stock management, and supplier diversification. Conclusion: Interruptions of anticancer drugs threaten the continuity of treatments and patient safety. Stable access requires increased production, diversification of sources, better stock management, and optimized communication.

Keywords: Anticancer drugs, interruption, chemotherapy, clinical impact.